Epidemiology

• the geographical regions most frequently studied for disease prevalence include Europe and the USA. In Europe, estimates derived from self-reporting of disease
  within large cohort or population samples range from 1·0% to 2·1%, whereas estimates based on diagnosis codes range from 0·09% to 0·51%. (1)
• HS occurs more commonly in females (a female to male ratio of approximately 3:1) (2,3)
• it does not start before puberty and hormonal factors are thought to play a role. The average age of onset is 21 years (4)
• patients first enter hospital settings at the age of 38y (3)

Reference:

1. Sabat R et al. Hidradenitis suppurative. Lancet 2025; 405: 420–38
2. Ingram JR, Jenkins-Jones S, Knipe DW, et al. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018 Apr;178(4):917-24
3. Hasan S B, Harris C, Collier F. Hidradenitis suppurativa BMJ 2022; 379 :e068383 doi:10.1136/bmj-2021-068383
4. Collier F, Smith RC, Morton CA; Diagnosis and management of hidradenitis suppurativa. BMJ. 2013 Apr 23;346:f2121